Literature DB >> 28243969

Diuretic Strategies in Acute Decompensated Heart Failure.

E Ashley Hardin1, Justin L Grodin2.   

Abstract

PURPOSE OF REVIEW: The burden of heart failure in the United States is growing rapidly to epic proportions with serious clinical implications for patients and economic strain for healthcare systems. One of the most common reasons for hospitalization in acute decompensated heart failure (ADHF) is excess volume accumulation which leads to untoward symptoms including dyspnea,orthopnea, and edema. RECENT
FINDINGS: Over the past several decades, there has been great interest in exploring various decongestive strategies in order to achieve symptomatic improvement and favorable clinical outcomes. These include different modalities of loop diuretic administration, the adjunctive use of non-loop diuretics, and other diuretic sparing strategies. Herein, we provide an appraisal of these decongestive strategies and discuss novel concepts predicting clinical outcomes based on diuretic response and decongestive adequacy while discussing commonly encountered problems such as worsening renal function in ADHF.

Entities:  

Keywords:  Acute decompensated heart failure; Decongestive; Diuretic; Heart failure

Mesh:

Substances:

Year:  2017        PMID: 28243969     DOI: 10.1007/s11897-017-0319-y

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  51 in total

1.  Diuretic response in acute heart failure-an analysis from ASCEND-HF.

Authors:  Jozine M ter Maaten; Allison M Dunning; Mattia A E Valente; Kevin Damman; Justin A Ezekowitz; Robert M Califf; Randall C Starling; Peter van der Meer; Christopher M O'Connor; Phillip J Schulte; Jeffrey M Testani; Adrian F Hernandez; W H Wilson Tang; Adriaan A Voors
Journal:  Am Heart J       Date:  2015-05-09       Impact factor: 4.749

2.  Clinical trial of bumetanide versus furosemide in patients with congestive heart failure.

Authors:  L L Konecke
Journal:  J Clin Pharmacol       Date:  1981 Nov-Dec       Impact factor: 3.126

3.  Diuretic strategies in patients with acute decompensated heart failure.

Authors:  G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

Review 4.  Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?

Authors:  Robert W Schrier
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

5.  Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.

Authors:  Robert J Mentz; Susanna R Stevens; Adam D DeVore; Anuradha Lala; Justin M Vader; Omar F AbouEzzeddine; Prateeti Khazanie; Margaret M Redfield; Lynne W Stevenson; Christopher M O'Connor; Steven R Goldsmith; Bradley A Bart; Kevin J Anstrom; Adrian F Hernandez; Eugene Braunwald; G Michael Felker
Journal:  JACC Heart Fail       Date:  2014-10-31       Impact factor: 12.035

6.  Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure.

Authors:  Justin L Grodin; Susanna R Stevens; Lisa de Las Fuentes; Michael Kiernan; Edo Y Birati; Divya Gupta; Bradley A Bart; G Michael Felker; Horng H Chen; Javed Butler; Victor G Dávila-Román; Kenneth B Margulies; Adrian F Hernandez; Kevin J Anstrom; W H Wilson Tang
Journal:  J Card Fail       Date:  2015-07-21       Impact factor: 5.712

7.  Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure.

Authors:  Begoña López; Arantxa González; Javier Beaumont; Ramón Querejeta; Mariano Larman; Javier Díez
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

8.  Urinary composition during decongestive treatment in heart failure with reduced ejection fraction.

Authors:  Frederik H Verbrugge; Petra Nijst; Matthias Dupont; Joris Penders; W H Wilson Tang; Wilfried Mullens
Journal:  Circ Heart Fail       Date:  2014-07-18       Impact factor: 8.790

9.  Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.

Authors:  A A van Vliet; A J Donker; J J Nauta; F W Verheugt
Journal:  Am J Cardiol       Date:  1993-01-21       Impact factor: 2.778

10.  Anti-aldosteronergic effect of torasemide.

Authors:  T Uchida; K Yamanaga; M Nishikawa; Y Ohtaki; H Kido; M Watanabe
Journal:  Eur J Pharmacol       Date:  1991-11-26       Impact factor: 4.432

View more
  3 in total

1.  Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.

Authors:  Christopher S Wilcox; Wen Shen; David W Boulton; Bruce R Leslie; Steven C Griffen
Journal:  J Am Heart Assoc       Date:  2018-02-10       Impact factor: 5.501

2.  Risk factors for renal failure and short-term prognosis in patients with spontaneous intracerebral haemorrhage complicated by acute kidney injury.

Authors:  Zhenhuan Zou; Siying Chen; Yinshuang Li; Jiawei Cai; Yulu Fang; Jingzhi Xie; Wenhua Fang; Dezhi Kang; Yanfang Xu
Journal:  BMC Nephrol       Date:  2020-07-29       Impact factor: 2.388

3.  Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials.

Authors:  Guang Ma; Xixi Ma; Guoliang Wang; Wei Teng; Xuezhi Hui
Journal:  BMJ Open       Date:  2019-05-01       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.